Cargando…

Comparison Between Liver Stiffness Measurement by Fibroscan and Splenic Volume Index as NonInvasive Tools for the Early Detection of Oxaliplatin-induced Hepatotoxicity

BACKGROUND: Oxaliplatin remains an essential component of many chemotherapy protocols for gastrointestinal cancers; however, neurotoxicity and hepatotoxicity may be dose-limiting. The gold standard for the diagnosis of oxaliplatin-induced hepatotoxicity is liver biopsy, which is invasive and costly....

Descripción completa

Detalles Bibliográficos
Autores principales: Bouferraa, Youssef, Haibe, Yolla, Jabra, Elio, Charafeddine, Maya, Kreidieh, Malek, Raad, Randa, Temraz, Sally, Mukherji, Deborah, Ershaid, Firas, Muallem, Nadim, Faraj, Walid, Khalife, Mohamad, Eid, Rania A., Shamseddine, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077221/
https://www.ncbi.nlm.nih.gov/pubmed/35535062
http://dx.doi.org/10.1016/j.jceh.2021.06.007
_version_ 1784702077220421632
author Bouferraa, Youssef
Haibe, Yolla
Jabra, Elio
Charafeddine, Maya
Kreidieh, Malek
Raad, Randa
Temraz, Sally
Mukherji, Deborah
Ershaid, Firas
Muallem, Nadim
Faraj, Walid
Khalife, Mohamad
Eid, Rania A.
Shamseddine, Ali
author_facet Bouferraa, Youssef
Haibe, Yolla
Jabra, Elio
Charafeddine, Maya
Kreidieh, Malek
Raad, Randa
Temraz, Sally
Mukherji, Deborah
Ershaid, Firas
Muallem, Nadim
Faraj, Walid
Khalife, Mohamad
Eid, Rania A.
Shamseddine, Ali
author_sort Bouferraa, Youssef
collection PubMed
description BACKGROUND: Oxaliplatin remains an essential component of many chemotherapy protocols for gastrointestinal cancers; however, neurotoxicity and hepatotoxicity may be dose-limiting. The gold standard for the diagnosis of oxaliplatin-induced hepatotoxicity is liver biopsy, which is invasive and costly. Splenomegaly has also been used as a surrogate for liver biopsy in detecting oxaliplatin-induced sinusoidal obstruction syndrome (SOS), but splenic measurement is not routine and can be inaccurate and complex. We investigated the correlation between increased liver elasticity assessed by Fibroscan and the increase in spleen volume on cross-sectional imaging after oxaliplatin as a noninvasive technique to assess liver stiffness associated with oxaliplatin-induced SOS. METHODS: Forty-six patients diagnosed with gastrointestinal cancers and planned to take oxaliplatin containing regimens were included in this prospective study at the American University of Beirut Medical Center (AUBMC). Measurement of spleen volume using cross-sectional imaging and of liver elasticity using Fibroscan was performed at baseline, 3 and 6 months after starting oxaliplatin. Mean liver elasticity measurements were compared between patients stratified by the development of splenomegaly using the Student t-test. Splenomegaly was defined as 50% increase in spleen size compared with baseline. RESULTS: Patients who developed splenomegaly after oxaliplatin use had significantly higher mean elasticity measurements as reported by Fibroscan at 3 (16.2 vs. 7.8 kPa, P = 0.036) and 6 (9.3 vs. 6.7 kPa, P = 0.03) months. CONCLUSION: Measurement of elasticity using Fibroscan could be potentially used in the future as a noninvasive test for predicting oxaliplatin-induced hepatotoxicity.
format Online
Article
Text
id pubmed-9077221
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90772212023-03-01 Comparison Between Liver Stiffness Measurement by Fibroscan and Splenic Volume Index as NonInvasive Tools for the Early Detection of Oxaliplatin-induced Hepatotoxicity Bouferraa, Youssef Haibe, Yolla Jabra, Elio Charafeddine, Maya Kreidieh, Malek Raad, Randa Temraz, Sally Mukherji, Deborah Ershaid, Firas Muallem, Nadim Faraj, Walid Khalife, Mohamad Eid, Rania A. Shamseddine, Ali J Clin Exp Hepatol Original Article BACKGROUND: Oxaliplatin remains an essential component of many chemotherapy protocols for gastrointestinal cancers; however, neurotoxicity and hepatotoxicity may be dose-limiting. The gold standard for the diagnosis of oxaliplatin-induced hepatotoxicity is liver biopsy, which is invasive and costly. Splenomegaly has also been used as a surrogate for liver biopsy in detecting oxaliplatin-induced sinusoidal obstruction syndrome (SOS), but splenic measurement is not routine and can be inaccurate and complex. We investigated the correlation between increased liver elasticity assessed by Fibroscan and the increase in spleen volume on cross-sectional imaging after oxaliplatin as a noninvasive technique to assess liver stiffness associated with oxaliplatin-induced SOS. METHODS: Forty-six patients diagnosed with gastrointestinal cancers and planned to take oxaliplatin containing regimens were included in this prospective study at the American University of Beirut Medical Center (AUBMC). Measurement of spleen volume using cross-sectional imaging and of liver elasticity using Fibroscan was performed at baseline, 3 and 6 months after starting oxaliplatin. Mean liver elasticity measurements were compared between patients stratified by the development of splenomegaly using the Student t-test. Splenomegaly was defined as 50% increase in spleen size compared with baseline. RESULTS: Patients who developed splenomegaly after oxaliplatin use had significantly higher mean elasticity measurements as reported by Fibroscan at 3 (16.2 vs. 7.8 kPa, P = 0.036) and 6 (9.3 vs. 6.7 kPa, P = 0.03) months. CONCLUSION: Measurement of elasticity using Fibroscan could be potentially used in the future as a noninvasive test for predicting oxaliplatin-induced hepatotoxicity. Elsevier 2022 2021-06-15 /pmc/articles/PMC9077221/ /pubmed/35535062 http://dx.doi.org/10.1016/j.jceh.2021.06.007 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Bouferraa, Youssef
Haibe, Yolla
Jabra, Elio
Charafeddine, Maya
Kreidieh, Malek
Raad, Randa
Temraz, Sally
Mukherji, Deborah
Ershaid, Firas
Muallem, Nadim
Faraj, Walid
Khalife, Mohamad
Eid, Rania A.
Shamseddine, Ali
Comparison Between Liver Stiffness Measurement by Fibroscan and Splenic Volume Index as NonInvasive Tools for the Early Detection of Oxaliplatin-induced Hepatotoxicity
title Comparison Between Liver Stiffness Measurement by Fibroscan and Splenic Volume Index as NonInvasive Tools for the Early Detection of Oxaliplatin-induced Hepatotoxicity
title_full Comparison Between Liver Stiffness Measurement by Fibroscan and Splenic Volume Index as NonInvasive Tools for the Early Detection of Oxaliplatin-induced Hepatotoxicity
title_fullStr Comparison Between Liver Stiffness Measurement by Fibroscan and Splenic Volume Index as NonInvasive Tools for the Early Detection of Oxaliplatin-induced Hepatotoxicity
title_full_unstemmed Comparison Between Liver Stiffness Measurement by Fibroscan and Splenic Volume Index as NonInvasive Tools for the Early Detection of Oxaliplatin-induced Hepatotoxicity
title_short Comparison Between Liver Stiffness Measurement by Fibroscan and Splenic Volume Index as NonInvasive Tools for the Early Detection of Oxaliplatin-induced Hepatotoxicity
title_sort comparison between liver stiffness measurement by fibroscan and splenic volume index as noninvasive tools for the early detection of oxaliplatin-induced hepatotoxicity
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077221/
https://www.ncbi.nlm.nih.gov/pubmed/35535062
http://dx.doi.org/10.1016/j.jceh.2021.06.007
work_keys_str_mv AT bouferraayoussef comparisonbetweenliverstiffnessmeasurementbyfibroscanandsplenicvolumeindexasnoninvasivetoolsfortheearlydetectionofoxaliplatininducedhepatotoxicity
AT haibeyolla comparisonbetweenliverstiffnessmeasurementbyfibroscanandsplenicvolumeindexasnoninvasivetoolsfortheearlydetectionofoxaliplatininducedhepatotoxicity
AT jabraelio comparisonbetweenliverstiffnessmeasurementbyfibroscanandsplenicvolumeindexasnoninvasivetoolsfortheearlydetectionofoxaliplatininducedhepatotoxicity
AT charafeddinemaya comparisonbetweenliverstiffnessmeasurementbyfibroscanandsplenicvolumeindexasnoninvasivetoolsfortheearlydetectionofoxaliplatininducedhepatotoxicity
AT kreidiehmalek comparisonbetweenliverstiffnessmeasurementbyfibroscanandsplenicvolumeindexasnoninvasivetoolsfortheearlydetectionofoxaliplatininducedhepatotoxicity
AT raadranda comparisonbetweenliverstiffnessmeasurementbyfibroscanandsplenicvolumeindexasnoninvasivetoolsfortheearlydetectionofoxaliplatininducedhepatotoxicity
AT temrazsally comparisonbetweenliverstiffnessmeasurementbyfibroscanandsplenicvolumeindexasnoninvasivetoolsfortheearlydetectionofoxaliplatininducedhepatotoxicity
AT mukherjideborah comparisonbetweenliverstiffnessmeasurementbyfibroscanandsplenicvolumeindexasnoninvasivetoolsfortheearlydetectionofoxaliplatininducedhepatotoxicity
AT ershaidfiras comparisonbetweenliverstiffnessmeasurementbyfibroscanandsplenicvolumeindexasnoninvasivetoolsfortheearlydetectionofoxaliplatininducedhepatotoxicity
AT muallemnadim comparisonbetweenliverstiffnessmeasurementbyfibroscanandsplenicvolumeindexasnoninvasivetoolsfortheearlydetectionofoxaliplatininducedhepatotoxicity
AT farajwalid comparisonbetweenliverstiffnessmeasurementbyfibroscanandsplenicvolumeindexasnoninvasivetoolsfortheearlydetectionofoxaliplatininducedhepatotoxicity
AT khalifemohamad comparisonbetweenliverstiffnessmeasurementbyfibroscanandsplenicvolumeindexasnoninvasivetoolsfortheearlydetectionofoxaliplatininducedhepatotoxicity
AT eidraniaa comparisonbetweenliverstiffnessmeasurementbyfibroscanandsplenicvolumeindexasnoninvasivetoolsfortheearlydetectionofoxaliplatininducedhepatotoxicity
AT shamseddineali comparisonbetweenliverstiffnessmeasurementbyfibroscanandsplenicvolumeindexasnoninvasivetoolsfortheearlydetectionofoxaliplatininducedhepatotoxicity